Theratechnologies (THTX)
(Delayed Data from NSDQ)
$1.26 USD
-0.02 (-1.56%)
Updated May 28, 2024 03:59 PM ET
After-Market: $1.26 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
THTX 1.26 -0.02(-1.56%)
Will THTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for THTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for THTX
Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?
Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock
THTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for THTX
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies to present Phase 1 data on Sudocetaxel Zendusortide at ASCO
Theratechnologies (THTX) Gets a Buy from JonesTrading
Theratechnologies Shareholders Elect Directors, Appoint Auditors
Theratechnologies Reports on its Annual Meeting of Shareholders